| Dr Vijay Ramchandra Randive, MD | |
|
6932j Market Street, Wilmington, NC 28411 | |
| (910) 799-1249 | |
| (910) 799-1249 |
| Full Name | Dr Vijay Ramchandra Randive |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 35 Years |
| Location | 6932j Market Street, Wilmington, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194824177 | NPI | - | NPPES |
| 0265L | Other | NC | BCBS |
| 70188 | Other | NC | BCBS |
| 8970188 | Medicaid | NC | |
| 890265L | Medicaid | NC |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davis Medical Center | Elkins, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Davis Memorial Hospital | 3072418540 | 69 |
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery works significantly better than traditional risk assessment tools.
Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).
› Verified 6 days ago
| Entity Name | Davis Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619964806 PECOS PAC ID: 3072418540 Enrollment ID: O20040107000438 |
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery works significantly better than traditional risk assessment tools.
Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vijay Ramchandra Randive, MD 6932j Market Street, Wilmington, NC 28411 Ph: (910) 799-1249 | Dr Vijay Ramchandra Randive, MD 6932j Market Street, Wilmington, NC 28411 Ph: (910) 799-1249 |
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery works significantly better than traditional risk assessment tools.
Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).
› Verified 6 days ago
Russell Anthony Incatasciato, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4402 Shipyard Blvd, Wilmington, NC 28403 Phone: 910-452-1400 Fax: 910-791-9626 | |
Kevin John Reese, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4402 Shipyard Blvd, Wilmington, NC 28403 Phone: 910-452-1400 Fax: 910-791-9626 | |
Michael Robert Ott, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4402 Shipyard Blvd, Wilmington, NC 28403 Phone: 910-452-1400 Fax: 910-332-1032 | |
Lisa A Plazzo, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4402 Shipyard Blvd, Wilmington, NC 28403 Phone: 910-452-1400 Fax: 910-791-9626 | |
Dr. Robert Lee Young, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2131 S 17th St, Wilmington, NC 28401 Phone: 910-667-7000 | |
Dr. Sean Patrick O'brien, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4402 Shipyard Blvd, Wilmington, NC 28403 Phone: 910-202-3363 Fax: 910-791-9626 | |
Kenneth Charles Marburg, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4402 Shipyard Blvd, Wilmington, NC 28403 Phone: 910-452-1400 Fax: 910-332-1072 |